## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report that bicyclo-nucleotide modified single-stranded DNA (ssDNA) exhibits enhanced binding to four protein targets relative to control ssDNA, as determined by 200 ns all-atom explicit solvent molecular dynamics (MD) simulations followed by MM-PBSA free energy calculations. They further attribute the enhanced binding to improved electrostatic complementarity, assessed via Delphi-based electrostatic calculations, and propose potential applications in anticancer and antisense therapeutic design.
- **Visible evidence base** Abstract text only; no quantitative data, simulation details, error estimates, or methodological parameters are provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, simulation setup details, force field parameters, convergence criteria, error bars, statistical analyses, and experimental binding free energy values referenced as "experimentally known"

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting application of MD simulations to evaluate modified nucleotide binding to proteins, with a plausible mechanistic hypothesis involving electrostatics. However, the evidence base available for review is limited to the abstract, which lacks quantitative results, methodological transparency, and statistical validation. The core claims of enhanced binding and electrostatic complementarity cannot be adequately assessed from the supplied material. The work may be of interest to computational biophysicists and nucleic acid chemists, but the current evidence does not establish the case.
- **Who would be interested in the results, and why** Computational chemists and biophysicists studying nucleic acid analogues and their interactions with proteins would find the approach relevant. Researchers in antisense and anticancer drug development may also be interested in the potential of bicyclo-nucleotides as therapeutic scaffolds, particularly if the enhanced binding and electrostatic mechanism are robustly validated.
- **Major strengths** The study addresses a relevant question in nucleic acid therapeutics, namely whether sugar-modified nucleotides can improve protein binding. The use of all-atom explicit solvent MD simulations with MM-PBSA is a standard and defensible approach for relative binding free energy estimation. The inclusion of four distinct protein systems provides some breadth, and the electrostatic hypothesis is mechanistically plausible and testable.
- **Major Concerns**  
  - **Concern ID** R1-M1  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Evidence sufficiency  
  - **Claim pointer** The abstract claims that "modified ssDNA displayed enhanced binding to proteins as compared to the control ssDNA" based on MD simulations and MM-PBSA calculations.  
  - **Evidence pointer** Abstract, results section (location not provided)  
  - **Concern** No quantitative data are presented in the abstract to support the claim of enhanced binding. No binding free energy values, differences, or statistical measures are provided. It is unclear whether the reported enhancement is consistent across all four systems, what the magnitude of the effect is, or whether the differences exceed simulation uncertainty.  
  - **Why it matters** Without quantitative results and error estimates, the central claim of enhanced binding cannot be evaluated. MM-PBSA is known to be sensitive to setup choices and often yields large uncertainties; the abstract provides no indication of convergence or reproducibility.  
  - **Resolution test** Provide numerical binding free energies for modified and control ssDNA for each system, with standard deviations or confidence intervals, and demonstrate that the differences are statistically significant and reproducible across independent simulations.  
  - **Concern ID** R1-M2  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Mechanistic support  
  - **Claim pointer** The abstract states that "the high binding of modified ssDNA to protein might be related to the enhanced electrostatic complementarity displayed by the modified ssDNA molecules in all the four systems."  
  - **Evidence pointer** Abstract, results section (location not provided)  
  - **Concern** The electrostatic complementarity claim is presented as a correlation without any quantitative correlation coefficient, decomposition analysis, or comparison to other energetic components. The abstract does not specify how electrostatic complementarity was quantified, whether it was compared to van der Waals or solvation contributions, or whether the relationship between electrostatics and binding is causal or merely correlative.  
  - **Why it matters** The mechanistic explanation is a key contribution of the work. If the electrostatic argument is not rigorously supported, the proposed design principle for therapeutic molecules is weakened.  
  - **Resolution test** Provide a quantitative electrostatic complementarity metric for each system, show a statistical correlation with binding free energies, and rule out alternative explanations such as entropic or hydrophobic effects.  
  - **Concern ID** R1-M3  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Methodological transparency  
  - **Claim pointer** The abstract describes "all-atom explicit solvent molecular dynamics (MD) simulations (200 ns)" and MM-PBSA calculations.  
  - **Evidence pointer** Abstract, methods section (location not provided)  
  - **Concern** The abstract provides no details on force field parameters for the modified nucleotides, water model, salt concentration, temperature and pressure coupling, equilibration protocol, or the number of independent simulations. The MM-PBSA protocol is not described, including the choice of solute and solvent dielectric constants, entropy contributions, or the number of frames used.  
  - **Why it matters** Reproducibility and reliability of MD-based free energy estimates depend critically on these parameters. Without this information, the technical soundness of the simulations cannot be assessed.  
  - **Resolution test** Provide a complete methods section with all simulation parameters, force field validation for the bicyclo-nucleotides, and a description of the MM-PBSA protocol including error estimation.  
  - **Concern ID** R1-M4  
  - **Severity** Major  
  - **Blocking** No  
  - **Axis** Validation against experiment  
  - **Claim pointer** The abstract states that "four ssDNA-protein complexes with experimentally known binding free energies" were used.  
  - **Evidence pointer** Abstract, introduction or methods (location not provided)  
  - **Concern** The abstract does not report how the simulated binding free energies for the control ssDNA compare to the experimental values. No validation metrics such as mean absolute error or correlation coefficient are provided.  
  - **Why it matters** Validation against experiment is essential to establish that the simulation protocol is reliable enough to support claims about modified nucleotides. Without this, the enhanced binding claim for modified ssDNA is not placed in a credible quantitative context.  
  - **Resolution test** Report the comparison between simulated and experimental binding free energies for the control systems, including errors and correlation statistics.

- **Minor Comments**  
  - **Concern ID** R1-m1  
  - **Severity** Minor  
  - **Axis** Clarity  
  - **Affected element** Abstract, first sentence  
  - **Evidence pointer** Abstract, introduction (location not provided)  
  - **Issue** The opening statement that DNA-protein interactions are "crucial determinants for the survival of a cell" is overly broad and not directly tied to the study's focus on modified nucleotides.  
  - **Required correction** Reframe the introduction to focus specifically on the role of modified nucleotides in modulating DNA-protein interactions for therapeutic purposes.  
  - **Concern ID** R1-m2  
  - **Severity** Minor  
  - **Axis** Terminology  
  - **Affected element** Abstract, description of bicyclo-nucleotides  
  - **Evidence pointer** Abstract, methods (location not provided)  
  - **Issue** The description of the bicyclo system with "C2' axis of symmetry" is unclear and may be confusing to readers unfamiliar with the chemistry.  
  - **Required correction** Provide a clearer chemical description or a reference to a prior publication detailing the synthesis and structure of these nucleotides.  
  - **Concern ID** R1-m3  
  - **Severity** Minor  
  - **Axis** Scope of implications  
  - **Affected element** Abstract, final sentence  
  - **Evidence pointer** Abstract, conclusion (location not provided)  
  - **Issue** The claim that improved binding "can be utilized to design and develop anticancer/antisense molecules" is speculative and not supported by any functional or cellular data in the abstract.  
  - **Required correction** Soften the claim to indicate that the results may inform future design efforts, pending further experimental validation.

## Risk / unsupported claims
- The claim of enhanced binding of modified ssDNA to proteins is unsupported by quantitative data in the abstract.
- The claim of enhanced electrostatic complementarity as the mechanistic basis is unsupported by any quantitative analysis.
- The claim of potential utility in anticancer and antisense therapeutic design is speculative and not supported by functional evidence.
- The validation of the simulation protocol against experimental binding free energies is not assessable from the abstract.
- The methodological details required to evaluate the reliability of the MD and MM-PBSA calculations are not provided.

## Assessment against Nature-style criteria
- **Originality** The concept of evaluating bicyclo-nucleotide modified ssDNA binding to proteins via MD simulations is moderately original, but the abstract does not clearly distinguish this work from prior studies on other sugar-modified nucleotides. The originality claim is weakened by the lack of comparative discussion.
- **Scientific importance** The potential therapeutic relevance of modified nucleotides is significant, but the abstract does not demonstrate that the reported effects are large enough or robust enough to have practical implications. The importance is therefore not established from the supplied evidence.
- **Interdisciplinary readership** The work bridges computational chemistry, nucleic acid chemistry, and drug discovery, which could appeal to a broad audience. However, the abstract is written in a way that assumes familiarity with MD and MM-PBSA methods, which may limit accessibility.
- **Technical soundness** The technical soundness cannot be assessed from the abstract alone. The absence of simulation parameters, force field details, and error analysis prevents evaluation of the reliability of the results.
- **Readability for nonspecialists** The abstract is concise but uses specialized terminology without sufficient context. The chemical description of bicyclo-nucleotides and the MM-PBSA method are not explained for a general scientific audience.

## Recommendation posture
Currently not established from the provided evidence. The abstract presents a plausible computational study, but the absence of quantitative results, methodological transparency, and statistical validation means that the core claims cannot be evaluated. The authors should be encouraged to provide the full manuscript with detailed methods, numerical results, and validation against experimental data. If those materials address the concerns raised, the work could become a useful contribution to the field of modified nucleic acid therapeutics.